Every source, chapter by chapter

Not a journal articleCDC, National Diabetes Statistics Report (prediabetes: ~96 million U.S. adults in the 2019 estimate; more than 8 in 10 do not know they have it).

Note: 96 million is the 2019 figure; later CDC reports revised the number upward (~97.6 million and, more recently, higher). The "more than 8 in 10 unaware" figure is current CDC language.

Athinarayanan SJ, Adams RN, Hallberg SJ, et al. "Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial." Front Endocrinol (Lausanne). 2019;10:348.

In the bookmore than half her patients did it, and it stuck at two years.

At two years, diabetes reversal was 53.5% and remission 17.6%.

Hallberg SJ, McKenzie AL, Williams PT, et al. "Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year." Diabetes Ther. 2018;9(2):583-612.

Backs "nearly all cut or quit insulin." At 1 year, insulin was reduced or eliminated in 94% of INSULIN USERS, not 94% of all participants. Only a subset of the 262 in the intervention arm were on insulin at baseline, so "of participants" overstates it. Sulfonylureas were eliminated entirely.

Kearns CE, Schmidt LA, Glantz SA. "Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents." JAMA Intern Med. 2016;176(11):1680-1685.

The Sugar Research Foundation secretly funded a 1965 NEJM review steering blame to fat.

Ioannidis JPA. "Why Most Published Research Findings Are False." PLoS Med. 2005;2(8):e124.

Not a journal articleYerushalmy J, Hilleboe HE. "Fat in the diet and mortality from heart disease: a methodologic note." N Y State J Med. 1957;57(14):2343-2354.

In the bookHe had data on 22, and kept the 6 that fit his theory.

Keys' 1953 six-country graph used 6 of the 22 countries for which data were available; the full 22-country picture was weaker.

Not a journal articleAmerican Diabetes Association conflicts of interest (Ch2). Sources: Reuters and Fox News (Nov 2023) on former ADA nutrition director Elizabeth Hanna, "pay to play" lawsuit; ADA 2022 Annual Report (Splenda listed among "elite" supporters giving more than $1 million); PR Newswire (Nov 2025), "Idaho Potatoes and the American Diabetes Association Team Up to Bust Common Nutrition Myths" (the "Mashing the Myth" campaign).

Confirmed in public reporting: the Splenda sponsorship; the "over a million dollars in a single year" line (the ADA 2022 report listed Splenda among elite $1M-plus supporters); the former-nutrition-director lawsuit, which remains an allegation; and the 2025 "Mashing the Myth" ADA and Idaho Potato Commission campaign on potatoes and blood sugar.

Levine H, Jorgensen N, Martino-Andrade A, et al. "Temporal trends in sperm count: a systematic review and meta-regression analysis." Hum Reprod Update. 2017;23(6):646-659.

Not a journal articleCDC/NCHS, "Prevalence of Overweight, Obesity, and Severe Obesity Among Adults" (Health E-Stat).

In the bookone in eight adults were obese. Now almost 75% of American adults are overweight or obese.

Obesity was 12.8% in 1960-62. In 2021-23 obesity was 40.3% and overweight another 31.7%, about 72% combined.

Not a journal articleUSDA Economic Research Service, Sugar and Sweeteners Yearbook Tables (per-capita caloric-sweetener availability, loss-adjusted).

In the bookBy 1999 we hit 158 pounds per person. We're still over 120 pounds today.

USDA ERS puts per-capita caloric-sweetener availability at ~153.6 lb at the 1999 peak (an earlier series lists 160.9 lb), declining to ~123.5 lb by 2023. The chapter figures fall within this range and the direction is correct.

Lustig RH. "Fructose: metabolic, hedonic, and societal parallels with ethanol." J Am Diet Assoc. 2010;110(9):1307-1321.

In the bookSugar is alcohol without the buzz. Same liver, same damage.

2026-09-06

Not a journal articleMelkonian EA, Asuka E, Schury MP. "Physiology, Gluconeogenesis." StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; last updated 13 November 2023.

In the bookgluconeogenesis

What gluconeogenesis actually is: making glucose out of substrates that are not glucose. It names three and where each comes from. Lactate, from anaerobic glycolysis in cells including exercising muscle and red blood cells. Glycerol, released from fat tissue when triglycerides are broken down. Glucogenic amino acids, entering through the citric acid cycle. It describes the Cori cycle this way: "The liver uses lactate in the blood to produce glucose via gluconeogenesis. Glucose gets released into the bloodstream, travels back to the erythrocytes and exercising muscles, and is metabolized back into lactate."

Tondt J, Yancy WS, Westman EC. Application of nutrient essentiality criteria to dietary carbohydrates. Nutr Res Rev. 2020;33(2):260-270. PMID 32102704.

"You don't have to eat carbs at all." The review states the body synthesises carbohydrate endogenously and shows no deficiency signs without dietary carbohydrate, and classes dietary carbohydrate as conditionally essential: not required for the general population, required in specific conditions such as glycogen storage disease type I. Counterevidence on file: Edens NK et al, Clin Chest Med 1986;7(1):3-17, PMID 3082577, argues the brain needs about 500 kcal of carbohydrate daily for zero nitrogen balance in acutely ill patients. Older, narrower, and not aimed at essentiality.

Stewart WK, Fleming LW. Features of a successful therapeutic fast of 382 days' duration. Postgrad Med J. 1973;49(569):203-209. PMID 4803438. PMC2495396.

The 382-day supervised fast in Chapter 4. From the abstract itself: a 27-year-old male fasted under supervision for 382 days, was ambulant and attending as an out-patient, and prolonged fasting had no ill-effects. The weights 456 lb and 180 lb are NOT in the abstract and the 1973 scan carries no machine-readable body text. They come from the paper's own sentence as quoted by two independent sources. Kyle approved shipping them on 2026-08-28. The 276 lb difference is not printed. The 1965 start date is newspaper-sourced and is not in the book.

Kraemer WJ, Ratamess NA. Hormonal responses and adaptations to resistance exercise and training. Sports Med. 2005;35(4):339-361. PMID 15831061.

A written decision NOT to make a claim. Kyle asked whether "insulin is the strongest signal to build and store" is defensible. This review calls testosterone and growth hormone anabolic and says insulin and IGF-1 are critical to muscle growth. It ranks nothing. Nothing found ranks insulin above them, so the word strongest stays out and Ch4 keeps the unranked sentence. Recorded so nobody re-opens it.

Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol. 1991;165(6 Pt 1):1667-1672. PMID 1750458.

Backs 'insulin sensitivity falls by about half by the third trimester and insulin climbs to match.' Six nonobese normal women, hyperinsulinaemic-euglycaemic clamp before conception and at 12-14 and 34-36 weeks. 56 percent fall in insulin sensitivity by 36 weeks, 3.0 to 3.5 fold rise in insulin release. CALIBRATION: n=6. It measures the change. It does not state a purpose, so the book must not put one in this source's mouth. Retrieved from PubMed 2026-08-28.

Apter D, Sipila I. Development of children and adolescents: physiological, pathophysiological, and therapeutic aspects. Curr Opin Obstet Gynecol. 1993;5(6):764-773. PMID 8286688.

Backs the puberty half: rising estradiol transiently increases growth hormone, which raises IGF-1, insulin resistance and physiological hyperinsulinaemia. This source DOES tie the insulin rise to growth, so the growth framing is sourced for puberty and not for pregnancy. Retrieved from PubMed 2026-08-28.

Louis M, Punjabi NM. "Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers." J Appl Physiol (1985). 2009;106(5):1538-1544.

Backs the glucose half of the night-alarm passage. Thirteen healthy volunteers, five hours of intermittent oxygen drops while awake, against a normoxia day. Insulin sensitivity fell and glucose disposal fell, and sympathetic activity rose. Cortisol did not change. The oxygen drops moved glucose handling on their own.

Ken-Dror G, Fry CH, Murray P, Fluck D, Han TS. "Changes in cortisol levels by continuous positive airway pressure in patients with obstructive sleep apnoea: Meta-analysis of 637 individuals." Clin Endocrinol (Oxf). 2021;95(6):909-917.

Backs the cortisol half, indirectly. Twenty-two studies, 637 people. Treating the apnea with CPAP lowered cortisol, and lowered blood pressure by about 5 points on the top number. The effect on cortisol is real but small.

Alomri RM, Kennedy GA, Wali SO, Alhejaili F, Robinson SR. "Association between nocturnal activity of the sympathetic nervous system and cognitive dysfunction in obstructive sleep apnoea." Sci Rep. 2021;11(1):11990.

Backs the morning number. In people with sleep apnea, morning blood glucose tracked with how long oxygen saturation stayed under 90 percent overnight.

van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39(2):81-93. PMID 19200161.

Backs 'High cortisol makes your cells listen to insulin less.' Review of glucocorticoid-induced insulin resistance and beta-cell dysfunction. CALIBRATION: this literature rests on pharmacological glucocorticoid doses and Cushing's syndrome, not on everyday psychological stress. The direction of the mechanism is established. The SIZE of the effect at ordinary stress levels is not established by this source and must not be implied. Retrieved from PubMed 2026-08-28.

Boivin DB, Boudreau P, Kosmadopoulos A. "Disturbance of the Circadian System in Shift Work and Its Health Impact." J Biol Rhythms. 2022;37(1):3-28. DOI: 10.1177/07487304211064218

In the bookWork the night shift and your body clock does not follow you.

A review of simulated night-shift experiments and field studies in shift workers. It reports that "the circadian system is resistant to adaptation from a day- to a night-oriented schedule, as determined by a lack of substantial phase shifts over multiple days in centrally controlled rhythms, such as those of melatonin and cortisol." The clock does not drift onto the new schedule. It stays put, and the worker lives against it.

Chen IY, Jarrin DC, Ivers H, Morin CM. "Investigating psychological and physiological responses to the Trier Social Stress Test in young adults with insomnia." Sleep Med. 2018;40:11-22. DOI: 10.1016/j.sleep.2017.09.011

In the bookCortisol can do that.

30 adults studied with polysomnography over two nights. "Increased cortisol response and elevated sympathovagal imbalance were each significantly associated with longer nocturnal awakenings (p = 0.048, p = 0.037)." An association in a small sample, which the authors call preliminary. It carries "can," not "that is."

Battelino T, Danne T, Bergenstal RM, et al. "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range." Diabetes Care. 2019;42(8):1593-1603.

Backs the 70 to 180 mg/dL clinical target. This is the consensus treatment goal for people with diabetes. Context for the glucose-variability line. The clinical stability threshold is a coefficient of variation of 36% or less; metabolically healthy people typically run under 25%.

Shah VN, DuBose SN, Li Z, et al. "Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study." J Clin Endocrinol Metab. 2019;104(10):4356-4364.

In the bookHealthy people without diabetes live between 70 and 140, about 96 percent of the day.

153 healthy people aged 7 to 80 wore a blinded sensor. Median time between 70 and 140 mg/dL was 96 percent, interquartile range 93 to 98.

Mo Y, Wang C, Lu J, et al. "Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study." Diabetes Res Clin Pract. 2022;189:109940.

In the bookThose swings have a name: glucose variability.

on variability. In 1,839 well-controlled patients (time-in-range >70%), higher glucose coefficient of variation still predicted all-cause mortality; the highest CV group (>35%) carried more than double the risk. Variability matters even when the average looks fine.

Mo Y, Lu J, Zhou J. "Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?" J Diabetes Investig. 2024;15(1):5-14.

Review of how glucose variability is measured, what targets are used, and the proposed mechanisms tying variability to tissue damage. Background for the chapter's coefficient-of-variation framing.

Yajnik CS. "Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries." J Nutr. 2004;134(1):205-210.

In the bookSouth Asians become insulin resistant at a BMI (body mass index) of 23.

Backs the thin-fat phenotype only: for a given BMI, Indians have a higher percentage of body fat and more visceral fat than other populations, present at birth. The paper gives NO BMI threshold and the number 23 does not appear in it. The BMI 23 action point comes from the WHO Expert Consultation, Lancet 2004;363(9403):157-163, DOI 10.1016/S0140-6736(03)15268-3.

Romeo S, Kozlitina J, Xing C, et al. "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease." Nat Genet. 2008;40(12):1461-1465.

Supports the Hispanic liver-fat gene. PNPLA3 I148M drives hepatic fat and is most common in Hispanics.

Ostbye T, Welby TJ, Prior IA, Salmond CE, Stokes YM. "Type 2 (non-insulin-dependent) diabetes mellitus, migration and westernisation: the Tokelau Island Migrant Study." Diabetologia. 1989;32(8):585-590.

Diabetes rose with migration from Tokelau to urban New Zealand.

Svetkey LP, McKeown SP, Wilson AF. "Heritability of salt sensitivity in black Americans." Hypertension. 1996;28(5):854-858.

Source for the salt-sensitivity figure. Salt sensitivity was found in 73% of hypertensive and 36% of normotensive Black adults. "About half" is a rough population average.

Schmidlin O, Forman A, Leone A, Sebastian A, Morris RC. "Salt sensitivity in blacks." Hypertension. 2011;58(3):380-385.

Mechanism study on how salt raises blood pressure in salt-sensitive Black adults.

Warburg O. "On the origin of cancer cells." Science. 1956;123(3191):309-314.

The 1924 German paper is "Über den Stoffwechsel der Carcinomzelle" (Naturwissenschaften 1924). "Über den Stoffwechsel der Tumoren" is the 1926 monograph. Neither is indexed in PubMed.

Lauby-Secretan B, Scoccianti C, Loomis D, et al. "Body Fatness and Cancer — Viewpoint of the IARC Working Group." N Engl J Med. 2016;375(8):794-798.

In the bookObesity and type 2 diabetes sit on the accepted list of cancer risk factors.

The IARC Working Group found sufficient evidence that absence of excess body fat lowers the risk of 13 cancers.

Giovannucci E, Harlan DM, Archer MC, et al. "Diabetes and Cancer: A Consensus Report." Diabetes Care. 2010;33(7):1674-1685 (also CA Cancer J Clin. 2010;60(4):207-221).

In the bookObesity and type 2 diabetes sit on the accepted list of cancer risk factors.

Joint American Diabetes Association and American Cancer Society consensus: type 2 diabetes is associated with increased risk of several cancers, including liver, pancreas, colorectum, breast, and endometrium.

WHO Expert Consultation. "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies." Lancet. 2004;363(9403):157-163. DOI: 10.1016/S0140-6736(03)15268-3

In the bookSouth Asians become insulin resistant at a lower BMI

Source of the BMI 23 action point for Asian populations.

Taylor R. "Type 2 diabetes and remission: practical management guided by pathophysiology." J Intern Med. 2020;289(6):754-770. PMID 33289165. PMC8247294.

The personal fat threshold. Retrieved from PubMed 2026-08-30. Its own words: remission is “independent of BMI, underscoring the personal fat threshold concept that type 2 diabetes develops when an individual acquires more fat than can be individually tolerated even at a BMI which in the nonobese range.” Taylor is at Newcastle University, which is what the book says. CALIBRATION: this is a narrative review of the author's own programme, not an independent trial.

Reaven GM. "Banting lecture 1988. Role of insulin resistance in human disease." Diabetes. 1988;37(12):1595-1607. PMID 3056758.

The quarter of lean people already insulin resistant. Retrieved from PubMed 2026-08-30. Its own words: insulin resistance is present “in approximately 25% of nonobese individuals with normal oral glucose tolerance.” Same paper anchors RULE 8 and positions P1 and P3 in rules/KYLE_IP_DOCTRINE.md.

Hieronimus B, Ensenauer R. "Influence of maternal and paternal pre-conception overweight/obesity on offspring outcomes and strategies for prevention." Eur J Clin Nutr. 2021;75(12):1735-1744. PMID 34131301. PMC8636250.

Both parents, before conception. Retrieved from PubMed 2026-08-30. Its own words: parental pre-conception overweight and obesity is a risk factor for overweight in childhood and beyond, and metabolic changes “affect epigenetic markers in oocytes and sperms alike.” CALIBRATION, and the book already carries it: this is a narrative review and the paper itself says the mechanisms are “still poorly defined.” The book must keep the words “the work on this is early.” This source covers PRECONCEPTION. It does NOT cover the in-utero clause, which has no source.

Shukla AP, Iliescu RG, Thomas CE, Aronne LJ. "Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels." Diabetes Care. 2015;38(7):e98-e99.

Shukla AP, Dickison M, Coughlin N, et al. "The impact of food order on postprandial glycaemic excursions in prediabetes." Diabetes Obes Metab. 2019;21(2):377-381.

In the bookLead with carbs and the spike drowns the fullness signal... Save them for last and fullness gets there first

Backs the food-order effect on glucose. Incremental glucose peaks were attenuated by more than 40% in both the protein-vegetables-first and vegetables-first conditions against carbohydrate first. the significant reduction in postprandial INSULIN was reported ONLY for the vegetables-first arm, not the protein-and-vegetables-first arm.

Anderwald C, Brabant G, Bernroider E, Horn R, Brehm A, Waldhäusl W, Roden M. "Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients." Diabetes. 2003;52(7):1792-1798. PMID 12829648.

Backs 'raise insulin and leptin climbs.' Retrieved from PubMed 2026-08-30. Hyperinsulinaemic-euglycaemic clamp, six nondiabetic controls and six type 2 patients. Their numbers: leptin ROSE 35 plus or minus 11 percent in controls (P<0.05) and 19 plus or minus 6 percent in the untreated type 2 group. Saline alone DECREASED leptin 19 percent, so the rise is insulin and not the infusion. CALIBRATION: n=6 per arm, acute clamp, not free living.

Damjanovic SS, Lalic NM, Pesko PM, et al. "Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients." J Clin Endocrinol Metab. 2006;91(7):2574-2581. PMID 16621911.

Independent replication of the direction in 8-3, from a study designed to ask something else. Retrieved from PubMed 2026-08-30. Ten gastrectomised adults, five-hour hyperinsulinaemic euglycaemic clamp. Their words: during euglycaemic hyperinsulinaemia leptin 'significantly rose' (P<0.001) while ghrelin, C-peptide, glucagon and adiponectin all fell. CALIBRATION: n=10, gastrectomised, and leptin was not the primary endpoint. It is corroboration, not a second trial.

Polito R, Messina G, Valenzano A, et al. "The Role of Very Low Calorie Ketogenic Diet in Sympathetic Activation..." Int J Environ Res Public Health. 2022;19(4):2253.

The paper reports a reduction in HEART RATE as an indicator of sympathetic activity, not a measured improvement in HRV. Both arms fell; only the very-low-calorie ketogenic arm reached significance (n=13 per arm). The authors say sympathovagal balance "can be modulated" and call for further study. The published title is "Heart Rate Variability and Sympathetic Activity Is Modulated by Very Low-Calorie Ketogenic Diet"

Dulloo AG, Jacquet J. "Adaptive reduction in basal metabolic rate in response to food deprivation in humans: a role for feedback signals from fat stores." Am J Clin Nutr. 1998;68(3):599-606. PMID 9734736.

In the bookthe men's resting burn had fallen further than their lost tissue could explain

Backs 'portion control turns the dial down.' Kyle asked for this by name on Ch9 C8: “Keys and the K rations, look this up.” Retrieved from PubMed 2026-08-30. This is a reanalysis of the classic Minnesota semi-starvation experiment, the 32 men Ancel Keys starved, at weeks 12 and 24 and after 12 weeks of restricted refeeding. Its finding is the one the book needs: basal metabolic rate fell BEYOND what the loss of lean and fat tissue explains, and the size of that extra drop tracked how depleted the fat stores were. Their words: an 'adaptive reduction in BMR' under 'an autoregulatory feedback control system.' CALIBRATION: 32 men, severe restriction, and it is a reanalysis of 1940s data, not a new trial.

Yoneshiro T, Aita S, Matsushita M, et al. "Recruited brown adipose tissue as an antiobesity agent in humans." J Clin Invest. 2013;123(8):3404-3408. PMID 23867622. PMC3726164.

In the bookSix weeks of daily cold raised both brown fat activity and the energy people burned in the cold

Backs the cold section. Kyle asked on Ch9 C4 and C14 whether the cold claim is theory or measured. It is measured, in humans. Retrieved from PubMed 2026-08-30. Healthy adults with LOW brown fat activity to start. Two hours a day at 17 degrees C for six weeks. Result: brown fat activity and cold-induced energy expenditure rose together and body fat mass fell, and the two changes were negatively correlated. Acute exposure at 19 degrees C raised energy expenditure on its own. CALIBRATION: small, and 2 hours a day for 6 weeks is a real dose. A cold shower is not that dose and the book must not imply it is.

Schwarz JM, Noworolski SM, Erkin-Cakmak A, et al. "Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity." Gastroenterology. 2017;153(3):743-752.

In the bookin nine days, the fat in their livers dropped by almost half.

41 children aged 9 to 18 with obesity and high sugar intake. Calories and macronutrients held the same, sugar swapped for starch. Median liver fat fell from 7.2% to 3.8%.

Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. "Prevalence of periodontitis in adults in the United States: 2009 and 2010." J Dent Res. 2012;91(10):914-920.

In the bookmore than 40 percent of adults over 30.

Over 47% of US adults aged 30 and older had periodontitis, about 64.7 million people.

Bard RL, Rubenfire M, Eagle K, Clarke NS, Brook RD. "Utility of C-reactive protein measurement in risk stratification during primary cardiovascular disease prevention." Am J Cardiol. 2005;95(11):1378-1379.

In the bookUnder 1.0 mg/L is ideal. Over 1.0 should trigger an investigation.

2026-09-06

Guyenet SJ, Carlson SE. "Increase in adipose tissue linoleic acid of US adults in the last half century." Adv Nutr. 2015;6(6):660-664.

In the bookIn 1959, linoleic acid was about 9 percent of the fat stored in an American body. By 2008 it was over 21 percent.

Systematic review of 37 studies reporting linoleic acid in the subcutaneous fat of US adults. The best-fit line rose from 9.1 percent in 1959 to 21.5 percent in 2008, a 136 percent increase, closely tracking how much linoleic acid people ate over the same period.

Wheless JW. "History of the ketogenic diet." Epilepsia. 2008;49 Suppl 8:3-5.

Backs the seizure history. Doctors introduced the ketogenic diet as an epilepsy treatment in the 1920s to copy what fasting did, and it was widely used for two decades before drugs displaced it.

Ramsden CE, Zamora D, Majchrzak-Hong S, et al. "Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)." BMJ. 2016;353:i1246.

In the bookThe corn oil group had nearly twice the rate of heart attack scarring in the heart muscle. Forty-one percent against twenty-two.

A double-blind trial in 9,423 people. Corn oil in place of saturated fat lowered serum cholesterol 13.8 percent and produced no survival benefit. Among the recovered autopsy records, 41 percent of the corn oil group showed at least one myocardial infarct against 22 percent of controls. Only 149 of 295 autopsy files were recovered, so the authors call the finding provisional.

Raichle ME, Gusnard DA. "Appraising the brain's energy budget." Proc Natl Acad Sci U S A. 2002;99(16):10237-10239.

In the bookIt uses roughly 20% of your total energy despite being about 2% of your body weight.

Citation retrieved from PubMed 2026-09-08, PMID 12149485, PMC124895.

Yu Y, Chen KC, Chen J. "Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis." World J Pediatr. 2019;15(1):26-36.

In the bookabout as well as steroids

and "five times the odds of a healed gut lining." Eighteen studies. Exclusive enteral nutrition matched corticosteroids for inducing remission, and beat them on endoscopic mucosal healing (odds ratio 5.24) and histological healing (odds ratio 4.78).

Levine A, Wine E, Assa A, et al. "Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial." Gastroenterology. 2019;157(2):440-450.

Backs "randomized seventy-eight kids" and "three out of four." At week 12, 75.6% on the whole-food diet (CDED plus partial enteral nutrition) were in corticosteroid-free remission against 45.1% in the comparator arm. The comparator had exclusive enteral nutrition for 6 weeks, then a free diet with 25% partial enteral nutrition from weeks 7 to 12, so at the endpoint it was NOT formula alone. "

Yanai H, Levine A, Hirsch A, et al. "The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial." Lancet Gastroenterol Hepatol. 2022;7(1):49-59.

The adult evidence. A pilot trial, not a definitive one.

Lewis JD, Sandler RS, Brotherton C, et al. "A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease." Gastroenterology. 2021;161(3):837-852.

Norwitz NG, Soto-Mota A. "Case report: Carnivore-ketogenic diet for the treatment of inflammatory bowel disease: a case series of 10 patients." Front Nutr. 2024;11:1467475.

Peppard PE, Young T, Barnet JH, et al. "Increased prevalence of sleep-disordered breathing in adults." Am J Epidemiol. 2013;177(9):1006-1014.

In the booktens of millions.

Backs the rising-with-obesity trend, and ONLY that. This paper reports prevalence of MODERATE TO SEVERE sleep-disordered breathing (AHI 15 or more): 10% of men 30-49, 17% of men 50-70, 3% of women 30-49, 9% of women 50-70, with relative increases of 14% to 55% over two decades. Applied to the US population those rates are roughly twelve to fifteen million, not tens of millions.

Young T, Evans L, Finn L, Palta M. "Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women." Sleep. 1997;20(9):705-706.

In the bookThe majority have never been diagnosed.

93% of women and 82% of men with moderate-to-severe apnea were undiagnosed.

Benjafield AV, Ayas NT, Eastwood PR, et al. "Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis." Lancet Respir Med. 2019;7(8):687-698. DOI: 10.1016/S2213-2600(19)30198-5

In the booktens of millions of Americans have sleep apnea

An estimated 936 million adults aged 30 to 69 have mild to severe obstructive sleep apnoea worldwide and 425 million have moderate to severe; the USA has the second highest number after China. FUNDING: ResMed, a CPAP manufacturer.

UK Prospective Diabetes Study (UKPDS) Group. "U.K. prospective diabetes study 16. Overview of 6 years therapy of type II diabetes: a progressive disease." Diabetes. 1995;44(11):1249-1258.

In the bookyou have often already lost more than half of your beta cell function

and the "progressive disease" framing. The paper documents progressive loss of beta-cell function; the ~50%-at-diagnosis figure comes from UKPDS HOMA modeling widely cited from this report. (No DOI in the PubMed record; cited by volume and pages.)

DeFronzo RA. "Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus." Diabetes. 2009;58(4):773-795.

In the bookIn 2008, a physician named Ralph DeFronzo stood up at the American Diabetes Association's most prestigious annual lecture.

Retrieved from PubMed 2026-09-08, PMID 19336687, PMC2661582. Not from memory.

Graham DJ, Campen D, Hui R, et al. "Risk of acute myocardial infarction and sudden cardiac death in patients treated with COX-2 selective and non-selective NSAIDs: nested case-control study." Lancet. 2005;365(9458):475-481.

Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE. "Production of insulin resistance by hyperinsulinaemia in man." Diabetologia. 1985;28(2):70-75.

Backs "forty hours." Normal volunteers infused with insulin for 40 hours at levels seen in obesity (25-35 mU/l). Glucose utilization and overall glucose metabolism were "slightly, but significantly" reduced against saline control (the authors’ own hedge). They conclude hyperinsulinaemia "can produce insulin resistance in man."

Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. "Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man." Diabetologia. 1994;37(10):1025-1035.

In the bookfour days

and "20 to 40 percent." Fifteen healthy young subjects, 72 to 96 hours of physiologic euglycaemic hyperinsulinaemia. Whole body glucose disposal fell 20-40%. The authors' own conclusion: hyperinsulinaemia "should be considered, not only as a compensatory response to insulin resistance, but also as a self-perpetuating cause of the defect in insulin action."

Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. "Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes." J Clin Endocrinol Metab. 2013;98(2):668-677.

Currie CJ, Peters JR, Tynan A, et al. "Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study." Lancet. 2010;375(9713):481-489.

Supporting cohort. 47,970 patients. Insulin-based regimens against oral combination therapy carried a hazard ratio of 1.49 (1.39-1.59) for all-cause mortality. The same paper found a U-shaped curve, with the lowest A1C decile (median 6.4%) also carrying elevated risk. Funded by Eli Lilly.

Holden SE, Jenkins-Jones S, Currie CJ. "Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes." PLoS One. 2016;11(5):e0153594.

Supporting cohort, dose relationship. 12,020 patients. Insulin plus metformin against insulin alone: adjusted hazard ratio 0.60 (0.52-0.68) for all-cause mortality.

ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, et al. "Basal insulin and cardiovascular and other outcomes in dysglycemia." N Engl J Med. 2012;367(4):319-328.

Not a journal articleAmerican College of Cardiology, ORIGIN trial summary (Outcome Reduction With Initial Glargine Intervention).

In the bookthe cardiologists who reviewed it.

The ACC summary concludes there "seems to be no role for long-acting insulin analogues in the initial management of IFG/IGT/early DM" and that oral agents, particularly metformin, have the most evidence in that population.

Dubin RL, Heymsfield SB, Ravussin E, Greenway FL. "Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps." Diabetes Obes Metab. 2024;26(12):5503-5518.

In the booka real share of the weight lost can be lean mass.

Fat-free-mass loss on GLP-1 agents ran 20 to 40 percent across trials, most above 25 percent.

Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. "Quantifying the effect of metformin treatment and dose on glycemic control." Diabetes Care. 2012;35(2):446-454.

In the bookThe effect is modest, a little more than one A1C point.

Metformin monotherapy lowered HbA1c by 1.12%.

Not a journal articleHimsworth HP. "Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types." Lancet. 1936;227(5864):127-130.

Yalow RS, Berson SA. "Immunoassay of endogenous plasma insulin in man." J Clin Invest. 1960;39(7):1157-1175.

Reaven GM. "Banting lecture 1988. Role of insulin resistance in human disease." Diabetes. 1988;37(12):1595-1607.

Backs the third beat only: Reaven’s 1988 Banting Lecture put insulin resistance and compensatory hyperinsulinemia at the centre of the cluster. The Himsworth 1936 split and the Yalow and Berson 1960 radioimmunoassay are NOT in this paper;

Ramsden CE, Zamora D, Majchrzak-Hong S, et al. "Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)." BMJ. 2016;353:i1246.

In the bookForty-one percent of the corn oil group had the scar of a heart attack in the heart muscle. Twenty-two percent of the controls did.

A double-blind trial in 9,423 people. Corn oil in place of saturated fat lowered serum cholesterol 13.8 percent and produced no survival benefit. Among the recovered autopsy records, 41 percent of the corn oil group showed at least one myocardial infarct against 22 percent of controls. Only 149 of 295 autopsy files were recovered, so the authors call the finding provisional.

Not a journal articleKeys A, Aravanis C, Blackburn HW, et al. "Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries." Acta Med Scand Suppl. 1966;460:1-392.

The Seven Countries Study, the work that hardened the diet-heart story into guidance. Cited for the claim that it cemented the belief, not for its findings.

Not a journal articleTaubes G. Good Calories, Bad Calories. New York: Alfred A. Knopf; 2007.

In the bookBefore the heart attack it was 165 mg/dL. On his last day in office it was 259.

Reports the Ivan Frantz interview on the Minnesota Coronary Experiment. Also reports Eisenhower's cholesterol record from his physician Howard Snyder's papers: after the 1955 heart attack Eisenhower dieted religiously and had his cholesterol measured ten times a year; his last measurement before the attack was 165 mg/dL; by April 1960 Snyder was under-reporting the results to him, noting that he told the President 209 when it was actually 259.

Cholesterol Treatment Trialists (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, et al. "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials." Lancet. 2010;376(9753):1670-1681.

The CTT individual-patient dataset referenced in the data-access point. Supports the statin-efficacy context while the chapter's claim (raw patient-level data never opened to truly independent review) stands.

Not a journal articleCDC/NCHS, "Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over" (NCHS Data Brief No. 177, 2014) and later NHANES analyses.

In the bookover 40 million Americans take a statin.

About 1 in 4 U.S. adults over 40 take a cholesterol-lowering drug; 93% of those are statins. The year is cited with the number.

Norwitz NG, Cromwell WC. "Oreo Cookie Treatment Lowers LDL Cholesterol More Than High-Intensity Statin therapy in a Lean Mass Hyper-Responder on a Ketogenic Diet: A Curious Crossover Experiment." Metabolites. 2024;14(1):73.

Backs the Oreo passage. A single subject. LDL fell from 384 to 111 on twelve Oreos a day, and from 421 to 284 on rosuvastatin 20 mg. The author states in the paper that it is not health advice.

Soto-Mota A, Flores-Jurado Y, Norwitz NG, et al. "Increased low-density lipoprotein cholesterol on a low-carbohydrate diet in adults with normal but not high body weight: A meta-analysis." Am J Clin Nutr. 2024;119(3):740-747.

In the bookforty-one controlled trials

and "opposite things in different bodies." 41 trials, 1,379 participants. In people with a body mass index under 25, LDL rose about 41 mg/dL. In people at 35 and above it fell about 7 mg/dL. Saturated fat intake was not significantly associated with the change.

Norwitz NG, Feldman D, Soto-Mota A, Kalayjian T, Ludwig DS. "Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a 'Lean Mass Hyper-Responder' Phenotype." Curr Dev Nutr. 2022;6(1):nzab144.

Defines the phenotype in 548 adults. The largest LDL rises occurred in people with the lowest body mass index and the best triglyceride-to-HDL ratios.

Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. "The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study." Am J Geriatr Pharmacother. 2012;10(5):296-302.

In the bookeighteen Alzheimer's patients.

Cognitive scores improved off the statin and fell again on rechallenge. Open label, no control group.

Adhikari A, Tripathy S, Chuzi S, Peterson J, Stone NJ. "Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies." J Clin Lipidol. 2021;15(1):22-32.

In the bookthe large reviews, covering more than a million, find no cognitive harm at all.

24 studies, 1,404,459 participants aged 60 and over.

Norwitz NG, Loh V. "A Standard Lipid Panel Is Insufficient for the Care of a Patient on a High-Fat, Low-Carbohydrate Ketogenic Diet." Front Med (Lausanne). 2020;7:97.

Supports asking for more than the LDL number.

Ramsden CE, Zamora D, Leelarthaepin B, et al. "Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis." BMJ. 2013;346:e8707.

In the bookWhen it came out, 16 percent of the safflower oil group had died of heart disease. Ten percent of the controls had.

A randomized trial in 458 men who had already had a coronary event. Safflower oil in place of animal fat raised death from coronary heart disease to 16.3 percent against 10.1 percent in controls, hazard ratio 1.74, P=0.04. The data went unpublished for forty years and was recovered in 2013.

Not a journal articleLasby CG. Eisenhower's Heart Attack: How Ike Beat Heart Disease and Held On to the Presidency. Lawrence: University Press of Kansas; 1997.

Archival history of Eisenhower's 1955 heart attack and the years after it, drawn from the records of his personal physician, Howard Snyder. The primary source for the cholesterol measurements and for Snyder's handling of them.

Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210-1222. PMID 34531021.

The statin muscle-symptom passage. 60 randomized, 49 completed 12 months. Mean daily symptom score 8.0 in no-tablet months, 16.3 on statin, 15.4 on placebo, no difference between the two (P=0.388). Nocebo ratio 0.90. 30 of 60 back on statins at 6 months.

Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials (StatinWISE). BMJ. 2021;372:n135. PMID 33627334.

Same passage. 200 n-of-1 trials, 151 analysed. No difference in muscle symptom scores, mean difference statin minus placebo -0.11 (95% CI -0.36 to 0.14), P=0.40. Two thirds of completers intended to restart statins.

Kristiansen O, Vethe NT, Peersen K, et al. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects. Eur Heart J Cardiovasc Pharmacother. 2021;7(6):507-516. PMID 32609361.

Third negative crossover trial. 77 randomized, 71 completed. Atorvastatin 40 mg did not affect muscle symptom intensity. Mean VAS difference 0.31 (95% CI -0.24 to 0.86).

U.S. Food and Drug Administration, Drug Safety Communication: "Important safety label changes to cholesterol-lowering statin drugs" (28 February 2012). [regulatory, non-journal]

In the bookIn 2012 the FDA added a memory-and-confusion note to every statin label.

Identified 2026-09-08 by source_coverage.py as a named-agency claim with a year and no entry behind it.

Hazell L, Shakir SAW. “Under-reporting of adverse drug reactions: a systematic review.” Drug Saf. 2006;29(5):385-396.

In the bookReviews of that system put the median at fewer than one in ten ever reported.

Mach F, Ray KK, Wiklund O, et al., European Atherosclerosis Society Consensus Panel. “Adverse effects of statin therapy: perception vs. the evidence.” Eur Heart J. 2018;39(27):2526-2539.

In the bookIn the trials that mattered, cognition was asked about, not tested.

Brooks GA, Mercier J. "Balance of carbohydrate and lipid utilization during exercise: the 'crossover' concept." J Appl Physiol (1985). 1994;76(6):2253-2261.

Backs the fuel crossover. The crossover point is the intensity where carbohydrate overtakes fat as the main fuel. Endurance training pushes it higher. The paper’s only quantitative anchors are low intensity at or below 45% of maximal oxygen uptake, where lipid is the main substrate after training, and hard intensity around 75%, where carbohydrate predominates. It gives NO 60 to 65 percent figure. The crossover point shifts with training, not with how hard a single session is.

Volek JS, Freidenreich DJ, Saenz C, et al. "Metabolic characteristics of keto-adapted ultra-endurance runners" (FASTER study). Metabolism. 2016;65(3):100-110.

Backs the 88 percent figure and the higher crossover. 20 elite ultra-endurance athletes, 10 low carb (average 20 months) and 10 high carb, 180 min at 64% VO2max. Peak fat oxidation was 2.3-fold higher (1.54 vs 0.67 g/min) and occurred at a higher percentage of VO2max (70.3% vs 54.9%). Fat contributed 88% vs 56% of energy. the paper found NO glycogen sparing. Resting muscle glycogen and depletion were similar in both groups (-64% after the run, -36% after recovery).

Noakes TD. "What Is the Evidence That Dietary Macronutrient Composition Influences Exercise Performance? A Narrative Review." Nutrients. 2022;14(4):862. DOI: 10.3390/nu14040862

In the bookliver glycogen depletion drives fatigue.

The review argues that blood glucose, reflecting liver glycogen rather than muscle glycogen, is the homeostatically protected variable driving the metabolic response to prolonged exercise. Note: the title and author list previously attached to this DOI belonged to a different paper (Noakes, Prins, Volek, D'Agostino, Koutnik, Front Physiol 2023;14:1150265), which covers the crossover point and says nothing about liver glycogen.

O'Hearn M, Lauren BN, Wong JB, Kim DD, Mozaffarian D. "Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018." J Am Coll Cardiol. 2022;80(2):138-151.

In the bookFewer than one in ten American adults is in optimal metabolic health. Nine out of ten are not.

Retrieved from PubMed 2026-09-05, PMID 35798448, PMC10475326. 55,081 US adults in NHANES. In 2017-2018 only 6.8 percent (95% CI 5.4 to 8.1) had optimal cardiometabolic health, defined across adiposity, blood glucose, blood lipids, blood pressure and absence of clinical cardiovascular disease. The proportion FELL from 1999-2000, p for trend 0.02. Optimal glucose levels fell from 59.4 to 36.9 percent over the same period. Their own words: US cardiometabolic health has been "poor and worsening."

Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. "Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications." J Diabetes Res. 2020;2020:7489795.

In the bookEvery spike also leaves glucose stuck to protein. That is glycation.

2026-09-06

Mishra T, Wang M, Metwally AA, et al. "Pre-symptomatic detection of COVID-19 from smartwatch data." Nat Biomed Eng. 2020;4(12):1208-1220.

In the bookSometimes your data knows you're sick before you do.

Retrieved from PubMed 2026-09-08, PMID 33208926, PMC9020268. Not from memory.

Yalow RS, Berson SA. "Immunoassay of endogenous plasma insulin in man." J Clin Invest. 1960;39(7):1157-1175.

In the bookInsulin has been measurable in human blood since 1960, and the first thing it was used for was telling early diabetics from non-diabetics.

Retrieved from PubMed 2026-09-08, PMID 13846364 and PMID 13846365. Not from memory.

Grundy SM, Cleeman JI, Daniels SR, et al. "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement." Circulation. 2005;112(17):2735-2752.

In the bookThe threshold is 35 inches for women and 40 inches for men.

Retrieved from PubMed 2026-09-08, PMID 16157765 and PMID 19805654. Not from memory.

Staten MA, Stern MP, Miller WG, Steffes MW, Campbell SE. "Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care." Diabetes Care. 2010;33(1):205-206.

In the bookIn 2010 they published two pages in their own journal, and they asked for it to be fixed.

Retrieved from PubMed 2026-09-08, PMID 20040676, PMC2797975. Not from memory.

Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP, Campbell SE, Steffes MW. “Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup.” Clin Chem. 2007;53(4):711-716.

In the bookSend the same blood anywhere and the number comes back the same. Your A1C works that way. Your insulin does not.

An ADA Workgroup evaluated 12 different commercial insulin methods from 9 manufacturers. Among-assay CVs ranged from 12% to 66%, with a median of 24%. The paper's own finding on the fix everyone assumed would work: “A common insulin reference preparation did not change the among-assay CV and failed to improve harmonization of results among assays.”

Isokuortti E, Zhou Y, Peltonen M, et al. “Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.” Diabetologia. 2017;60(10):1873-1882.

In the bookThe published cutoffs move with the population and the lab that ran the test.

Ten samples were analysed for HOMA-IR in seven European laboratories. In the paper's own words: “The 2.0 HOMA-IR measured in Helsinki corresponded to 1.3, 1.6, 1.8, 1.8, 2.0 and 2.1 in six other laboratories.” Inter-laboratory CV was 25%, and it was the insulin measurement that carried it at 25% rather than the glucose at 5%. Two Finnish population cohorts put the upper 95th percentile of HOMA-IR at 1.9 and 2.0.

Rohlfing C, Petroski G, Hatten-Beck M, Hanson S, Hoofnagle AN, Little RR, Kabytaev K. “The current status of serum insulin measurements and the need for standardization.” Clin Chem Lab Med. 2025;63(12):2442-2446.

In the bookThey do not standardize insulin.

Forty serum samples run by nine manufacturers across 12 commercial immunoassays, each compared against isotope dilution mass spectrometry. Differences relative to the reference method ran from -298.2 to +302.6 pmol/L. Only one assay method showed full agreement with it. The paper's own conclusion: “Despite all methods claiming traceability to the WHO 66/304 standard, significant variability persists among insulin assays.”

O'Donnell M, Mente A, Rangarajan S, et al. "Urinary sodium and potassium excretion, mortality, and cardiovascular events." N Engl J Med. 2014;371(7):612-623.

Supports the J-curve. Lowest risk with estimated sodium 3-6 g/day; risk rose below 3 g/day (odds ratio 1.27) and above ~6-7 g/day.

Mente A, O'Donnell M, Rangarajan S, et al. "Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study" (PURE). Lancet. 2018;392(10146):496-506.

Cardiovascular harm from sodium appeared mainly in communities above 5 g/day. This is a contested area.

Not a journal articleAmerican Heart Association, sodium recommendation (ideal limit 1,500 mg/day).

Supports the AHA 1,500 mg line.

Lustig RH. "Fructose: metabolic, hedonic, and societal parallels with ethanol." J Am Diet Assoc. 2010;110(9):1307-1321.

In the bookRobert Lustig changed how I see food addiction. Food scientists engineer products to hit reward circuits.

2026-09-06

Norwitz NG, Sethi S, Palmer CM. "Ketogenic diet as a metabolic treatment for mental illness." Curr Opin Endocrinol Diabetes Obes. 2020;27(5):269-274.

Supports the brain-energy framing. Names four shared mechanisms across psychiatric conditions: glucose hypometabolism, neurotransmitter imbalance, oxidative stress, and inflammation.

Norwitz NG, Mota AS, Norwitz SG, Clarke K. "Multi-Loop Model of Alzheimer Disease: An Integrated Perspective on the Wnt/GSK3B, alpha-Synuclein, and Type 3 Diabetes Hypotheses." Front Aging Neurosci. 2019;11:184.

In the bookIt's what some researchers call Alzheimer's

A peer-reviewed review treating it as a named hypothesis and tying it to alpha-synuclein, the protein central to Parkinson's.

American Diabetes Association, "About Us", diabetes.org/about-us: mission "to prevent and cure diabetes and to improve the lives of all people affected by diabetes." [organizational, non-journal]

In the bookTheir mission says prevent. It has said prevent since 1988.

Retrieved 2026-09-04 during batch 215. Re-checked and entered here 2026-09-08.